Treosulfan (dihydroxybusulphan) in the management of ovarian carcinoma.

  • Joseph Fennelly
  • Published 1977 in British journal of obstetrics and gynaecology


Of 36 patients with ovarian carcinoma treated with treosulfan (dihydroxybusulphan) 30-5 per cent had a complete response for a mean of 19-0 months and 33-3 per cent had a partial response. Treosulfan may have a role in the management of ascites associated with ovarian neoplasm. 


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics